These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1427 related articles for article (PubMed ID: 31214177)

  • 81. Natural killer cells: a promising immunotherapy for cancer.
    Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
    J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.
    Ingegnere T; Mariotti FR; Pelosi A; Quintarelli C; De Angelis B; Tumino N; Besi F; Cantoni C; Locatelli F; Vacca P; Moretta L
    Front Immunol; 2019; 10():957. PubMed ID: 31114587
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
    Sutlu T; Alici E
    J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Development of NK cell-based cancer immunotherapies through receptor engineering.
    Page A; Chuvin N; Valladeau-Guilemond J; Depil S
    Cell Mol Immunol; 2024 Apr; 21(4):315-331. PubMed ID: 38443448
    [TBL] [Abstract][Full Text] [Related]  

  • 86. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The rise of human stem cell-derived natural killer cells for cancer immunotherapy.
    Wang K; Han Y; Cho WC; Zhu H
    Expert Opin Biol Ther; 2019 Feb; 19(2):141-148. PubMed ID: 30583701
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells.
    Han B; Song Y; Park J; Doh J
    J Control Release; 2022 Mar; 343():379-391. PubMed ID: 35124129
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The prospect of genetically engineering natural killer cells for cancer immunotherapy.
    Poon AYC; Sugimura R
    Biol Open; 2022 Dec; 11(12):. PubMed ID: 36445164
    [TBL] [Abstract][Full Text] [Related]  

  • 92. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.
    Bashiri Dezfouli A; Yazdi M; Pockley AG; Khosravi M; Kobold S; Wagner E; Multhoff G
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943898
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 94. Update on the current revolution in cancer immunotherapy.
    Renrick AN; Dunbar ZT; Shanker A
    Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010
    [No Abstract]   [Full Text] [Related]  

  • 95. Leveraging natural killer cells for cancer immunotherapy.
    Grossenbacher SK; Aguilar EG; Murphy WJ
    Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Memory-like natural killer cells for cancer immunotherapy.
    Gang M; Wong P; Berrien-Elliott MM; Fehniger TA
    Semin Hematol; 2020 Oct; 57(4):185-193. PubMed ID: 33256911
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
    Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
    BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
    Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
    BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.